MULTI- AND MANY-OBJECTIVE OPTIMISATION: PRESENT AND FUTURE IN *de novo* DRUG DESIGN

A PREPRINT

August 29, 2023

ABSTRACT

de novo Drug Design (dnDD) aims to create new molecules that satisfy multiple conflicting objectives. Since several desired properties can be considered in the optimisation process, dnDD is naturally categorised as a many-objective optimisation problem (ManyOOP), where more than three objectives must be simultaneously optimised. However, a large number of objectives typically pose several challenges that affect the choice and the design of optimisation methodologies. Herein, we cover the application of multi- and many-objective optimisation methods, particularly those based on Evolutionary Computation and Machine Learning techniques, to enlighten their potential application in dnDD. Additionally, we comprehensively analyse how molecular properties used in the optimisation process are applied as either objectives or constraints to the problem. Finally, we discuss future research in many-objective optimisation for dnDD, highlighting two important possible impacts: i) its integration with the development of multi-target approaches to accelerate the discovery of innovative and more efficacious drug therapies and ii) its role as a catalyst for new developments in more fundamental and general methodological frameworks in the field.

Keywords Drug discovery · *de novo* drug design · evolutionary algorithms · multi-objective optimisation · many-objective optimisation

1 Introduction

Life involves choices, reaching decisions and seeking compromises. The major challenge lies in managing the conflict between the various goals and objectives. As in many real-world problems, the discovery of a new drug with desired pharmacological and pharmacokinetic properties has several objectives to be considered. For instance, in the search for new therapeutic drugs, the maximisation of (i) the potency of the drug, (ii) the structural novelty, (iii) pharmacokinetic profile, the minimisation of (iv) synthesis costs, and (v) unwanted side effects are desired goals to be optimised Rosenthal and Borschbach (2017); Lambrinidis and Tsantili-Kakoulidou (2021). Thus, designing new effective and safe drugs is inherently a problem with diverse objectives to be optimised concurrently.

Many computational tools have been developed to assist in the design of novel drug-like molecules, such as molecular docking and affinity prediction through machine learning-based scoring functions Santos et al. (2020); Guedes et al. (2021). Flurbiprofen, vaborbactam and atazanavir are commercially approved drugs discovered by computer-aided drug design Sabe et al. (2021). The term "de novo" in Latin means "anew", "afresh", or "from the beginning". The goal of de novo drug design (dnDD) is to create novel molecules with desirable properties from scratch. In this context, multiple properties mean multiple objectives to be optimised.

The problem of optimisation refers to the task of discovering feasible solutions until no better solution can be found. The quality of a solution is evaluated based on an objective, while the feasible region represents a set of conditions or

^{*}Corresponding author: dardenne@lncc.br

[†]These authors contributed equally to this work and share first authorship.

constraints that limit the solutions to the problem. In dnDD, an objective can be expressed by various properties of interest, such as a similarity score to a known ligand or a binding score with a target receptor Nicolaou et al. (2009). At the same time, the constraints may be any useful function, such as chemical stability and synthetic feasibility Nicolaou and Kannas (2012).

For a long time, researchers in dnDD neglected the presence of multiple conflicting objectives Nicolaou et al. (2009), such as simultaneously maximise the potency of a drug to a specific target and minimise known side effects, which are naturally present in this type of problem. Due to the complexity of designing a new molecule, a single objective may not cover the multi-faceted design issues. Thus, researchers seek new techniques or design strategies that simultaneously consider the multiple aspects of this class of problems.

While in a single-objective optimisation problem (SingleOOP), the goal is to optimise only one objective function, in a multi-objective optimisation problem (MultiOOP), more than one objective must be simultaneously optimised. If the objective functions are not conflicting, a solution can be found where each objective reaches its optimum value. However, in MultiOOPs, those objectives are frequently conflicting (*i.e.*, the improvement of one objective leads to the degradation of another objective), and also non-commensurable (*i.e.*, when dealing with objectives that have different units or scales of measurement). In this case, there is usually no optimal solution but a set of trade-off solutions representing a compromise between the conflicting objectives. Such solutions are called *non-dominated* solutions, which form the *Pareto (optimal) set*, which is the set of solutions that are all equally optimal concerning the considered objectives.

An automatic dnDD can accelerate the overall drug discovery process but can be complex and computationally demanding. Since LEGEND, the first dnDD technique proposed in 1991 Nishibata and Itai (1991), numerous other methods have been developed to assist researchers in drug discovery. In particular, Evolutionary Algorithms (EAs) have been widely used to find the optimal solution(s) in *de novo design* Devi et al. (2015); Le and Winkler (2015). EAs are population-based metaheuristics in which a collection of candidate solutions evolve under specified selection rules to a state that minimises/maximises a general cost function. In contrast to classical search methods that usually aggregate the objective functions into one objective, EAs can be easily applied to multi-objective optimisation problems due to their population-based nature, allowing EAs to find a set of non-dominated solutions in a single run. Such methods are called multi-objective EAs (MultiOEAs).

Research in evolutionary computation has primarily focused on problems having two or three objectives Coello et al. (2007). However, many real-world problems have several (more than three) objectives in their formulation, *e.g.*, car side-impact Deb et al. (2009), mechanical engineering problems Ursem and Justesen (2012), water resource management Asafuddoula et al. (2015), routing planning in agricultural mobile robots Zhang et al. (2022), wireless sensor network deployment Ben Amor et al. (2022), among others. Particularly, dnDD has intrinsically various objectives to optimise, clearly more than three.

In this context, "multi-objective" refers to scenarios involving three objective functions at most, while "many-objective" is usually adopted to specify problems with more than three objectives. The growing interest in the area of many-objective optimisation (ManyOO) motivated the study and the design of new optimisation techniques capable of solving problems with four to twenty or even more objective functions. However, problems with many objectives present additional challenges when compared to low-dimensional problems, *e.g.*, finding a good approximation of the Pareto set. Many-objective optimisation in real-world applications has many decision design components that users commonly undertake Deb et al. (2023).

In this way, over the past three decades, many-objective EAs (ManyOEAs) have been the subject of extensive research and practical implementation in various real-world applications, making them a widely studied and applied field Safi et al. (2018); Sato and Ishibuchi (2023).

This paper aims to review and enlighten the potential application of ManyOO in dnDD, with particular emphasis on EAs. There have been a limited number of examples where ManyOEAs are applied to dnDD and published in scientific literature. Thus, the main contributions of this paper are:

- introduce the definition of ManyOOPs and discuss the main challenges that impact the choice and the design of evolutionary techniques when the number of objectives of an optimisation problem increases;
- review the different classifications of EAs for solving multi-objective and many-objective optimisation problems;
- present and classify some existing MultiOEAs for dnDD;
- enumerate and categorise several ManyOEAs, from the most representative to the most recent state-of-the-art techniques, which have the potential to be applied in dnDD;

- present recent research that employs machine learning techniques, as they are emerging as a promising class of methods for multi-objective and possibly for many-objective dnDD;
- provide a comprehensive analysis of how the various molecular properties used in the optimisation process are applied as either objectives or constraints to the problem.

As far as we know, this is the first review covering the application of ManyOO methodologies for the dnDD in addition to the MultiOO approaches. To organise and classify the different methodologies employed in these two main areas, "multi-objective" and "many-objective", herein, we classify the optimisation algorithms into two classes: *multi-objective methods*, in which problems are defined with two or three objectives, and *many-objective methods*, where problems contain four or more objectives, as illustrated in Figure 1.




Figure 1: Classes of optimisation methods adopted in this work, where k is the number of objectives. Flowchart generated with the Miro program (https://miro.com/).

The paper is organised as follows. Section 2 provides basic concepts and definitions regarding Pareto optimality and solutions methods for solving MultiOOPs, including classical techniques and MultiOEAs. Section 4 presents the main challenges faced when dealing with ManyOOPs. A classification of ManyOEAs is provided, presenting recent and representative methods for each approach. In Section 5, we describe applications in dnDD, focusing on the two classifications of methods proposed (multi-objective and many-objective), presenting not only techniques based on EAs but also based on Machine Learning (ML) methods. Recently, hybrid approaches have emerged, combining EAs with ML techniques to increase the potential of these two classes of methods. Additionally, we will discuss how researchers distinguish objectives and constraints among the many molecules' properties in dnDD. Perspectives concerning the ManyOO approach in dnDD are given in Section 6. The conclusions are presented in Section 7.

2 Key Concepts in the Multi-objective Optimisation Problem

A MultiOOP can be written as

$$\begin{array}{ll} \text{Minimise} & \mathbf{F}(\mathbf{x}) = (f_1(\mathbf{x}), f_2(\mathbf{x}), ..., f_k(\mathbf{x}))^T \\ \text{subject to} & g_j(\mathbf{x}) \leq 0, & j = 1, 2, ..., J; \\ & h_p(\mathbf{x}) = 0, & p = 1, 2, ..., P; \\ & x_i^l \leq x_i \leq x_i^u, & i = 1, 2, ..., n \end{array}$$

where we have $k(\geq 2)$ objective functions $f_i: \mathbb{R}^n \to \mathbb{R}$ that must be minimised. The vector of objective functions is denoted by $\mathbf{F}(\mathbf{x})$, where $\mathbf{x} = (x_1, x_2, ..., x_n)^T$ is a solution (decision) vector with n variables. Associated with the problem, there are J inequality and P equality constraints, such that $g: \mathbb{R}^n \to \mathbb{R}^J$ and $h: \mathbb{R}^n \to \mathbb{R}^P$, respectively. The

last set of constraints in (1) is the bound constraints that restrict each variable of the decision vector \mathbf{x} to a value within a lower x_i^l and an upper x_i^u bound, with i=1,...,n. A feasible solution is any solution \mathbf{x} that satisfies all constraints, and the set of all feasible solutions constitutes the feasible (set) region $S \subset \mathbb{R}^n$, which is a subset of the *decision space*.

The notable difference between single-objective and multi-objective optimisation is that in MultiOOP, the objective functions constitute a multi-dimensional space called the *objective space* $Z \subset \mathbb{R}^k$. The elements of Z correspond to the objective vector $\mathbf{z} = \mathbf{F}(\mathbf{x}) = (z_1, z_2, ..., z_k)^T$, where $z_i = f_i, \forall i = 1, ..., k$. For each solution vector \mathbf{x} in the decision space, there is an objective vector \mathbf{z} in the objective space. Such mapping relates an n-dimensional solution vector (in the decision space) to a k-dimensional objective vector (in the objective space). An illustrative example of these two spaces is shown in Figure 2. For clarity, suppose that A, B and C are three different compounds and f_1 and f_2 are affinity predictions given in pK_i of each molecule against two different targets (e.g., one therapeutic protein and one protein considered as an off-target related to side effects). Our objectives are to maximise the affinity value of these compounds against "target 1" and to minimise the affinity against "target 2". Hence, for each solution in the decision space (e.g., represented by the SMILES of a particular molecule), there is a corresponding point in the objective space (represented by the affinity prediction of the compound against each target).




Figure 2: Hypothetical decision space (a) and objective space (b) associated with objectives f_1 and f_2 for the molecules A, B and C represented by the SMILES strings.

2.1 Pareto optimality

In MultiOOP, several objectives must be simultaneously optimised. Usually, no single solution would give the best values for all the objective functions. Instead, in a typical MultiOOP with conflicting objectives, a set of solutions is superior to the others when all objectives are considered. Such solutions are those where none of the objectives can be improved without deteriorating at least one of the other objectives. Those solutions are called *Pareto-optimal solutions* due to the Italian economist Vilfredo Pareto, who introduced this theory in 1896 Pareto (1964). The optimal solution for a MultiOOP is based on the Pareto optimality concept, in which two solutions are compared based on whether one dominates the other.

Definition 2.1 A decision vector
$$\mathbf{x} \in S$$
 dominates another vector $\mathbf{y} \in S$ ($\mathbf{x} \prec \mathbf{y}$) if and only if $f_i(\mathbf{x}) \leq f_i(\mathbf{y}) \quad \forall i \in \{1,...,k\} \quad and \quad \exists j \in \{1,...,k\} : f_j(\mathbf{x}) < f_j(\mathbf{y})$

where k is the number of objectives.

Definition 2.2 A decision vector $\mathbf{x}^* \in S$ is a Pareto-optimal solution if no other $\mathbf{x} \in S$ dominates \mathbf{x}^* . The set of all Pareto optimal solutions in the decision space is called Pareto-optimal set, or simply Pareto set (PS), and its image in the objective space is called Pareto-optimal front, or Pareto front (PF).

The Pareto-optimal set is the best collection of solutions to the MultiOOP. Research in the area of MultiOO is concerned with the problem of how to identify the PS or at least a good approximation of it. The ideal approach would be to find

(i) a set of solutions as close as possible to the PF and (ii) as diverse as possible along that front Deb (2001). A typical PF is illustrated in Figure 3, where f_1 and f_2 are two objective functions that must be simultaneously minimised. Four different points (solutions values) are shown in this figure: solution A dominates solution B, as $f_1(A) < f_1(B)$ and $f_2(A) < f_2(B)$; A also dominates solution C for the same reason. However, solutions A and D are non-dominated by each other since $f_1(A) < f_1(D)$ but $f_2(A) > f_2(D)$. The Pareto-optimal solutions (dots in blue) that form the PF are those in which no objective can be improved without making at least one other objective worse.

The concept of dominance is of the utmost importance in this type of optimisation problem, as it allows the comparison of two different solutions concerning distinct objective functions. Hence, to find the non-dominated set of solutions, the dominance relation \prec is used to identify the best between two given solutions.




Figure 3: Pareto-optimal solutions for a two-objective minimisation problem.

3 Solution methods

There are different ways to deal with a MultiOOP, usually consisting of three stages: model building, optimisation, and decision-making Branke et al. (2008). First, we formulate the optimisation problem in which the decision variables, objectives and constraints are specified. Second, an optimisation technique is used to find the best compromise solutions. Since the Pareto optimal solutions are equally acceptable, a decision maker (DM), who usually has expertise in the problem domain, must decide which solution(s) best suits your preferences. Following the approaches that distinguish when the DM interacts with the optimisation procedure, the methods can be classified as Miettinen (1999):

- No-preference: no information about the importance of the objectives is assumed, and the DM's preferences are not considered. The problem can be solved by any method used to find a single optimum solution. The solution obtained is presented to the DM, which will accept or reject it.
- *A priori*: the hopes and opinions of the DM are taken into consideration before the solution process. Usually, one preferred Pareto-optimal solution is obtained. Those methods, known as *preference-based*, require the DM to know the priority of each objective beforehand.
- A posteriori: the PS is first generated, and then the DM is supposed to select the most preferred solution from this set of alternatives. The preference information is considered after the optimisation process.
- Interactive: the DM preferences are progressively used during the search procedure and are adjusted as the search continues.

The most intuitive and simple way to solve a MultiOOP is to convert it into a SingleOOP. The so-called *classical methods* mainly propose different ways of scalarising the objectives. These are commonly used methods that have existed for many decades. To obtain different Pareto-optimum solutions, the SingleOOP must be solved several times, with different parameters for finding solutions in the entire Pareto-optimum region.

Differently, *multi-objective evolutionary methods* seek to optimise the problem in its original form, with independent objectives, providing in each execution a set of Pareto-optimal solutions. The following sections will briefly outline some classical and MultiOEAs for solving MultiOOPs.

3.1 Classical methods

Classical methods basically transform the MultiOOP into a SingleOOP. Most of them are *aggregation-based* techniques, which aggregate the objective functions into one objective. Only one Pareto-optimal solution can be found in these methods at each execution.

3.1.1 The weighted sum method

The weighted sum method is probably the most used classical approach due to its simplicity and ease of use. In this technique, a weighting coefficient is associated with each objective function, and a weighted sum of the objectives is minimised. For each function f_i , there is a weight w_i associated, such that $0 \le w_i \le 1$ for all i = 1, ..., k, with $\sum_{i=1}^k w_i = 1$ (weights are normalised). By using this technique, the MultiOOP given in equation (1) is converted into a SingleOOP as follows Miettinen (1999):

Minimise
$$\sum_{i=1}^{k} w_i f_i(\mathbf{x})$$
 subject to $\mathbf{x} \in S$ (2)

It is recommended to normalise the objective functions so that they can be approximately in the same magnitude. If the weight coefficients are all positive or the solution to the problem is unique, then every solution this method finds is a Pareto-optimal solution. Also, for problems having a convex² PF (see in Figure 3), this method guarantees to find solutions on the entire PS Miettinen (1999). However, in the case of non-convex (see Figure 2 (b)) or non-connected PF, the use of a particular w does not guarantee that an arbitrary element of the PS is obtained Pardalos et al. (2018). Another issue is the difficulty of setting the weight vectors to obtain a Pareto-optimal solution in a desired region of the objective space since different weight vectors do not necessarily lead to different Pareto-optimal solutions Deb (2001). As an *a priori* method, the weights are specified before the optimisation process according to the preferences of the DM. It can also be extended to the interactive form, where the DM can interactively modify the weight coefficients after each iteration.

3.1.2 The weighted Tchebycheff method

Given an *ideal point* 3 \mathbf{z}^* , the MultiOOP can be transformed into the SingleOOP of the form Miettinen (1999):

$$\begin{array}{ll} \text{Minimise} & \max_{i=1}^{k} [w_i | f_i(\mathbf{x}) - z_i^*|] \\ \text{subject to} & \mathbf{x} \in S \end{array} \tag{3}$$

where $w_i \ge 0$ for all i = 1, ..., k and $\sum_{i=1}^k w_i = 1$. The weighted Tchebycheff method guarantees to find every Pareto-optimal solution to any problem if \mathbf{z}^* is a utopian vector Miettinen (1999). However, if \mathbf{z}^* is unknown, a reference point $\overline{\mathbf{z}}$ can be used instead. By specifying a reference point, the procedure is directed towards a particular region of the PF, whereas a given weight vector guides the procedure towards a Pareto-optimal point Deb and Sundar (2006).

Considering that the ideal approach for solving MultiOOPs would be to find many different trade-off solutions as close as possible to the PF and as diverse as possible along that front, it becomes clear that classical methods need a great effort to meet these goals. As they combine multiple objectives into one, some knowledge of the problem is required. Note that the optimisation of a single objective results in a single-point solution. In this way, multiple runs must be performed to generate different alternatives to the DM. Moreover, if the variable space is discontinuous and some objectives have many local minima, these methods may not work properly Srinivas and Deb (1994).

Conversely, EAs have become extremely popular over the last years as a non-classical, stochastic search technique to solve MultiOOPs. Next, we present a short overview of this methods class and their main differences compared to the classical approaches.

3.2 Multi-objective Evolutionary Algorithms (MultiOEAs)

The process of evolution of species inspires EAs and differ from classical methods in various ways. The most prominent is using a population of candidate solutions instead of a single solution, as in classical methods. This characteristic

²A set $C \subset \mathbb{R}^n$ is said to be convex when given $x, y \in C$, the segment $[x, y] = \{(1 - t)x + ty : t \in [0, 1]\}$ is contained in C.

³An ideal point is an objective vector that minimises each objective function.

allows those methods to find many Pareto-optimal solutions in a single run. Although they do not guarantee to find the optimal trade-off solutions, they can provide a satisfactory approximation set, which is (hopefully) not too far away from the true PF.

In the field of evolutionary computation, Genetic Algorithms (GAs) are the most popular ones. Developed by J. H. Holland in the '60s Holland (1962, 1975), they are based on the evolution of a population of individuals. Initially, a population of candidate solutions is randomly generated. For every individual, an objective function associates a fitness value indicating its suitability to the problem. At each iteration, individuals are selected to form the parents. Those parents are reproduced using different operators (*e.g.*, crossover, mutation) to generate new offsprings. Then, a replacement scheme is applied to determine which individuals of the population will survive from the offsprings and the parents. This process is repeated until a stopping criterion is reached.

Following these baseline steps, GAs are known to be very efficient in solving real problems in several fields Slowik and Kwasnicka (2020). As they do not require additional information about the problem, like continuity or differentiability, they are also well-suitable to solve black-box optimisation problems⁴.

The need to find trade-off solutions as close as possible to the Pareto optimal front (good convergence) and as diverse as possible along that front (good diversity) are the most important issues in MultiOOP. Therefore, search algorithms must be designed to obtain multiple solutions, each offering a different trade-off for the objective functions. In a simplistic case, this may be achieved by storing each found solution in an "archive" that maintains only non-dominated solutions. The way this archive is maintained, how individuals are selected and recombined, whether elitism is used or not, and how fitness assignment is applied characterise the various MultiOEAs. They can be classified into three main categories according to the different strategies employed Emmerich and Deutz (2018).

3.2.1 Pareto-based

The earliest attempts for solving MultiOOPs with MultiOEAs were based on the Pareto dominance relation. The main idea is that the fitness value is assigned to individuals based on the Pareto-dominance principle to achieve good convergence. An explicit diversity preservation scheme is also employed to maintain the diversity of solutions. Some of the most representative techniques of this class of methods are the Strength Pareto EA (SPEA/SPEA-II) Zitzler and Thiele (1998, 1999); Zitzler et al. (2001), the Pareto Archived Evolution Strategy (PAES) Knowles and Corne (1999, 2000), the Niched Pareto GA (NPGA/NPGA2) Horn et al. (1994); Erickson et al. (2001) and the Non-dominated Sorting GA (NSGA/NSGA-II) Srinivas and Deb (1994); Deb et al. (2002).

The primary concern with the Pareto-based approach arises when the number of objectives increases, particularly beyond three objectives. In such cases, it becomes increasingly challenging for these techniques to select solutions, as most of the solutions in the population tend to be non-dominated by one another. Section 4 discusses some of the main difficulties that arise when the number of objectives increases.

3.2.2 Indicator-based

In this approach, performance metrics, also known as quality indicators, are employed to define the selection mechanisms. Performance metrics are used to assess the quality of an approximation set generated by an algorithm. It assigns a real value to one or more approximation sets depending on certain quality aspects, such as (i) convergence toward the Pareto optimal region and (ii) diversity of solutions along the PF. The underlying idea of those techniques is to optimise the indicator value of the non-dominated set generated throughout the evolutionary process.

From the literature, it is not difficult to notice that the HV indicator is the most widely adopted metric for evaluating indicator-based optimisers and assessing non-dominated sets' quality. This metric calculates the volume of the dominated region by the obtained solution. Although there are many efforts to reduce the computational complexity of the HV computation, it is also known that the high computational cost involved when the number of objectives increases could limit the use of this metric Beume et al. (2009); Guerreiro and Fonseca (2018). However, the theoretical properties of the HV justify its widespread acceptance Zitzler et al. (2003).

A recent survey on indicator-based MultiOEAs can be found in Falcón-Cardona and Coello (2020a), where the authors presented solution methods from their origins up to their applications by current state-of-the-art approaches.

⁴In black-box optimisation, the objective function and/or constraints are approximated by computational methods that provide an answer (output) to the problem, given a set of input values. In practice, they often occur when the computation of the objective functions and/or constraints requires an expensive computer simulation or when their functional form are unknown.

3.2.3 Decomposition-based

The pioneering work on decomposition-based methods was due to Zhang and Li Zhang and Li (2007), who first proposed in 2007 the Multiobjective EA Based on Decomposition (MOEA/D). In this approach, the MultiOOP with k objectives is decomposed into M single-objective subproblems through some aggregation technique, for example, the weighted Tchebycheff approach (see Section 3.1).

These M subproblems, represented by M-weighted vectors, are simultaneously optimised in a single run. Different weight vectors need to be used to generate a set of Pareto-optimal solutions. The MOEA/D explores the neighbourhood relationship between these subproblems to solve the original problem in (1) efficiently.

A variety of methods was proposed for improving the design of the components of the MOEA/D, motivated by the existing limitations of the method. Later investigations tried to improve its performance by seeking new ways of, for instance, (i) decomposing the problem, (ii) generating the weight vectors, (iii) improving the efficiency of genetic operators, and iv) enabling the application of the method to ManyOOPs Trivedi et al. (2017); Xu et al. (2020).

4 Dealing with Many-Optimisation Problems

ManyOOPs are those having more than three objectives. As previously mentioned, drug design problems usually have more than three objectives to be optimised simultaneously, making them potential candidates for problems to be treated with ManyOO approaches.

4.1 Main Challenges

The presence of many objectives introduces several challenges that affect the choice and the design of evolutionary techniques. The difficulty of optimizing a large number of objectives is due to the so-called *curse of dimensionality*. The PF takes different forms depending on the number of objectives, *e.g.*, a two-objective problem results in a PF that is a curve or line, while a three-objective problem generates a PF that is a surface. As the number of objectives increases beyond four, the PF may be represented by a hypersurface or other higher-dimensional shape. Therefore, the number of solutions needed to represent the entire PF grows exponentially with the number of objectives Saxena et al. (2013). When the number of objective functions increases, one has to deal with the following issues Ishibuchi et al. (2008):

- almost all solutions in the population become non-dominated by each other, leading to a phenomenon called *dominance resistance* Purshouse and Fleming (2007). Such characteristic severely deteriorates the convergence of MultiOEAs:
- scaling issues may be encountered in choosing the appropriate size of the population since the number of points needed to approximate the entire Pareto front increase exponentially with the number of objectives Saxena et al. (2013);
- beyond 2D or 3D space, visualising the objective space becomes less intuitive, making it challenging to visually represent the obtained non-dominated solutions. Moreover, that makes it harder for the DM to choose the best solution. See, for example, the parallel coordinate plot in Figure 5 (a);
- performance metrics are also affected by the curse of dimensionality, *e.g.*, the HV and the IGD metrics have their performance compromised Ishibuchi et al. (2016);
- classical aggregation techniques (presented in section 3.1) are not limited to problems with up to three objectives. However, the difficulties pointed out in such methodology grow increasingly, *e.g.*, setting the weights of a large number of coefficients.

Given the aforementioned difficulties, the importance of treating ManyOOPs as a distinct class of problem is evident. In Allmendinger et al. (2022), the authors reflect on the question: "What if we increase the number of objectives?". In their paper, theoretical implications are presented on how the presence of many-objectives can impact the performance of MultiOEAs when solving the NK-landscapes problem Verel et al. (2013). They identified a series of drawbacks of dominance-based (e.g., NSGA-II Deb et al. (2002)), indicator-based (e.g., IBEA Zitzler and Künzli (2004)), and decomposition-based (e.g., MOEA/D Zhang and Li (2007)) MultiOEAs, along with recommendations for enhancing these techniques in the context of ManyOOPs. Thus, it is clear that MultiOEAs encounter performance limitations when applied to problems with more than three objectives. Therefore, evolutionary techniques that can be effectively applied to ManyOOPs are often referred to as ManyOEAs and represent the cutting edge of multi-objective optimization research. In the following sections, we will cover different EAs strategies to deal with ManyOOPs efficiently.

4.2 Many-objective Evolutionary Algorithms (ManyOEAs)

Unsurprisingly, new methods have been proposed to improve existing MultiOO techniques, and new methodologies have been developed in recent years. For readers interested in exploring existing many-objective algorithms across various domains, we recommend referring to the extensive list provided in the articles Mane and Narasinga Rao (2017); von Lücken et al. (2019). We will reference a few relevant strategies and introduce more recently published approaches. Herein, we classified ManyOEAs into five categories according to the approach adopted to treat the problem in a ManyOO context: relaxed dominance, indicator, decomposition, dimensionality reduction and hybrid techniques.

4.2.1 Relaxed dominance

As previously mentioned, when the number of objectives increases, almost all solutions in the population become non-dominated by each other. Hence, for MultiOEAs based on the Pareto dominance relation, the selection pressure towards the PF is compromised. A path explored to circumvent the scalability issue of dominance-based methods is to use relaxed forms of Pareto dominance to reduce the impact of dominance resistance. Such an approach can enhance the selection pressure toward the PF and provide a way of regulating the convergence of MultiOEAs.

Relaxed Pareto dominance (RPD) relations modify the Pareto dominance concept for better-discriminating solutions for selecting the best ones with enhanced selection pressure. The α -dominance Ikeda et al. (2001), ϵ -dominance Laumanns et al. (2002), cone ϵ -dominance Batista et al. (2011), θ -dominance Yuan et al. (2016), CN-dominance Dai et al. (2014), CN α -dominance Liu et al. (2019a), and MultiRPD Zhu et al. (2022) are some examples of RPDs. Figure 4 illustrates the dominated area of a solution \mathbf{x} using three different dominance relations: (a) the Pareto dominance, (b) the α -dominance and (c) the CN α -dominance for a bi-objective problem. Observe that the α -dominance and the CN α -dominance expand the domination area compared to the Pareto dominance. Under these relaxed definitions, a solution is expected to have a greater chance of being dominated by other solutions and the selection pressure towards the PF is enhanced.




Figure 4: Illustration of dominated areas by solution x using three dominance relations: (a) Pareto dominance, (b) α -dominance and (c) $CN\alpha$ -dominance.

In Li et al. (2015a), one can find diverse RPD-based methods, each applying a different RPD approach. Recently, the $CN\alpha$ -dominance proposed in Liu et al. (2019a) combines two existing dominance relations, the α -dominance Ikeda et al. (2001) and the CN-dominance Dai et al. (2014). The idea was to strengthen the selection pressure by expanding the dominated area by combining two other RPDs, as shown in Figure 4 (c). Computational experiments considered a non-dominated neighbour Immune Algorithm (NNIA) as the baseline method. The NNIA with the proposed $CN\alpha$ -dominance was compared against the NNIA with four different dominance relations. The results demonstrated the superiority of the $CN\alpha$ -dominance against different dominance relations in terms of solution quality and selection pressure on benchmark problems with five to fifty-five objectives.

4.2.2 Indicator

To improve the convergence ability of ManyOEAs, extensive research has been conducted on fitness evaluation mechanisms based on quality indicators Falcón-Cardona and Coello (2020b). As mentioned previously, the high-dimensional problem encountered in ManyOO may turn infeasible the application of HV-based MultiOEAs, despite the many efforts to mitigate its computational cost. The first method that attempted to accelerate the HV

computation and make it scalable for a large number of objectives was proposed by Bader *et al.* Bader et al. (2010); Bader and Zitzler (2011). The main idea of the hypervolume estimation algorithm (HypE) was not to calculate the exact values of the HV but instead to provide an estimate of this value through Monte Carlo simulations. Experimental results showed that HypE achieved competitive performance regarding the average HV on benchmark problems with up to fifty objectives.

The Two-archive methodology (Two-Arch/Two-Arch2) Praditwong and Yao (2006); Wang et al. (2015) was the first to divide the non-dominated solution set into two archives, one that promotes convergence (CA) and another that emphasises diversity (DA). CA and DA employ different updating rules that reflect their respective roles in the optimization process. In Two-Arch2, the update rule of CA is based on the quality indicator $I_{\epsilon+}$ from IBEA Zitzler and Künzli (2004), and the DA archive is updated based on the Pareto dominance rule. This method falls under the hybrid approach category. The results demonstrated that Two-Arch and Two-Arch2 outperformed other ManyOEAs in terms of convergence with comparable diversity quality in problems having two to eight objectives for the Two-Arch and up to twenty objectives for the Two-Arch2.

4.2.3 Decomposition

In decomposition-based methods, the ManyOOP is divided into several SingleOO subproblems using a set of weight vectors. The basic idea is to find a set of well-distributed, non-dominated solutions along the PF using generated weight vectors so the diversity of the population is controlled explicitly by weight vectors. Ideally, each solution in the population is associated with a subproblem.

The most representative algorithms of this class are the MOEA/DD Li et al. (2015b) and the NSGA-III Deb and Jain (2014); Jain and Deb (2014), which are extensions of the MOEA/D Zhang and Li (2007) and NSGA-III Deb et al. (2002), respectively. Those methods may also be classified as hybrid, employing a decomposition-based approach to maintain population diversity, while the Pareto dominance rule controls the algorithm's convergence. Both methods outperform many contemporary MultiOEAs. It is worth noting that the performance of those methods strongly depends on the shape of the PF Ishibuchi et al. (2017).

The MOEA/D with Update when Required (MOEA/D-UR) method de Farias and Araújo (2022) proposed a new scheme to adapt the weight vectors depending on whether they show signs of convergence. An additional technique for partitioning the objective space was proposed to increase the spread of individuals in the population to estimate the level of regularity of the PF's shape. The computational experiments show that the MOEA/D-UR has competitive performance compared to ten state-of-the-art ManyOEAs in test problems and real-world problems with up to fifteen objectives.

4.2.4 Dimensionality reduction

The visualisation of objectives in large dimensional space can be difficult. See, for example, Figure 5 (a), in which seven objective values are presented for many different solutions (each represented by a colour). The more pronounced the slope of the line connecting two solutions, the higher the likelihood of a possible conflict between them. In dimensionality reduction-based methods, the idea is to decrease the problem's difficulty by reducing the number of objectives by identifying redundant objectives Brockhoff and Zitzler (2006, 2007). For many problems, a smaller set of m (m < k) conflicting objectives exist that can generate the same PF as the original problem Yuan et al. (2018). For instance, Figure 5 shows the parallel coordinates plot of three solutions x_1 (blue), x_2 (red) and x_3 (yellow) and four objectives. The figure indicates that the objective functions f_1 and f_3 are redundant, since $f_1(x_1) < f_1(x_2) < f_1(x_3)$ as well as $f_3(x_1) < f_3(x_2) < f_3(x_3)$. Therefore, we can consider $\{f_1, f_2, f_4\}$ as the minimum objective set that preserves the dominance structure.

A list of many dimensionality reduction frameworks and ManyOEAs based on them is presented in Li et al. (2015a), in which the methods are classified as *online* and *offline*. Online methods reduce the number of objectives gradually during the search process. In contrast, offline methods reduce the number of objectives after obtaining the PS. These methods can reduce the computational load of ManyOEAs and assist DMs in distinguishing points based on non-redundant objectives. However, an open question is whether the loss of information can cause problems in the optimisation process.

A different approach for reducing the number of objectives was proposed by de Freitas et al. (2015), where the authors introduced the Aggregation Tree (AT). The AT tool allows the visualisation of redundancies and conflict between objectives in the form of a tree by using the concept of *harmony* to reduce the number of objectives. The more harmonic the two objectives are, the more suitable they are to be aggregated into a group of objectives without much loss in the representation of the PS. This technique was used in a multi-objective GA to solve a protein structure prediction




Figure 5: Parallel coordinate plots.

problem in which the AT was used to arrange seven terms of the energy function into a three-objective problem Rocha et al. (2017).

4.2.5 Hybrid approach

Hybrid techniques have been proposed to balance convergence and diversity in ManyOOPs. The method proposed in Zou et al. (2021), MOEADRA, is based on dominance and decomposition approaches. An elitism mechanism is exploited to balance the convergence and diversity of the evolutionary process. Simultaneously, a reference point adaptation scheme is designed to "learn" the true PF shape of different problems. Computational results showed that the MOEADRA outperformed seven state-of-the-art algorithms on various test problems with up to fifteen objectives.

The IDEA algorithm Xia et al. (2023) couples indicator-based and decomposition-based mechanisms. The decomposition-based approach promotes population diversity, while the I_{∞}^r Yuan et al. (2021) metric is used as the indicator value for achieving population convergence and distinguishing individuals. The performance of the method was evaluated on test problems with up to fifteen objectives. The results demonstrated that IDEA is effective in solving ManyOOPs.

5 Applications in de novo Drug Design

In the field of Computational Chemistry, MultiOO has been adopted for decades to obtain trade-offs among the objectives considered Handl et al. (2007); Ekins et al. (2010); Nicolotti et al. (2011); Parikh et al. (2023). A multitude of multi-objective approaches can be found in the literature, and we do not intend to describe or cite them exhaustively. This section describes some reported studies that explicitly apply multi-objective and many-objective strategies in dnDD. Following the previously defined classifications, the methodologies reviewed are mainly classified as aggregation-based and Pareto-based methods.

Recalling the preferences of the DM, the aggregation methods that will be cited in the next sections are mainly based on (i) *a priori* information, when the DM's preferences are considered before the optimisation process, and thus only a single final solution is generated, and (ii) *a posteriori* information, when a set of Pareto optimal solutions are generated for the DM to choose the best-suited solution.

5.1 MultiOO Methods: optimising up to three objectives

5.1.1 Aggregation-based

The GANDI algorithm Dey and Caffisch (2008) is a fragment-based approach that generates molecules by joining pre-docked fragments with a list of fragments provided by the user. In the paper, GA Holland (1975) and Tabu Search (TS) Glover and Laguna (1997) algorithms are used in combination to match those fragments. While the GA was used to generate new fragments by applying genetic operators, the TS was adopted to link those encoded fragments. GANDI

is an *a priori* method that scalarises the scoring functions into one, providing a single optimal solution. The weighted sum approach was used to aggregate three scoring functions to be minimised: a force field-based binding energy and two measures of similarity to a user-defined structure. Forbidden connections were avoided to prevent the generation of unstable molecules. When applied to the CDK2 kinase, the proposed method generated 1.809 molecules, of which eight were present in the ZINC database and commercially available Irwin and Shoichet (2005).

The method proposed by Devi et al. (2014) used a GA guided by the scalarisation of two objective functions, drug-likeness (by Lipinski's Rule of 5 Lipinski (2004)) and similarity (by Tanimoto similarity Loving et al. (2010)) to a known reference molecule from the e-Drug3D database. The weights of the objectives are set *a priori*. Two experiments were conducted, one using a local anaesthetic drug (lidocaine) and another using an anti-cancer molecule (furano-pyrimidine) as reference molecules. For each reference molecule, the authors analysed the proposed method using one (Tanimoto similarity alone) and two objectives (using a weighted sum of the similarity and drug-likeness functions). For the furano-pyrimidine molecule, the two-objective version of the method could generate drug-like molecules more efficiently than the one-objective formulation.

The MoGADdrug method, introduced in Devi et al. (2021), is a fragment-based GA that constructs new molecules from a set of chemical fragments and a reference molecule as inputs. Building upon previous work Devi et al. (2014), which considered only two fragments (acid and amine), this method incorporates a variable-length representation to construct new solutions considering double amine fragments, thus allowing three fragment types. The objective function is a weighted sum of the oral bio-availability score Lipinski (2004), and the 2D similarity based on the Tanimoto coefficient Brown (2009), with the weights being set *a priori*. The MoGADdrug could design drug-like molecules similar to lidocaine, furano-pyrimidine derivative, imatinib, atorvastatin and glipizide.

5.1.2 Pareto-based

The Compound Generator (CoG) method Brown et al. (2004) represents the first instance of a MultiOEA being applied in dnDD. The authors used Genetic Programming (GP), in which the topology of molecules is represented by graphs, where the graph nodes represent the atoms. Special mutation and crossover operators were implemented to generate new molecules, and no constraints were imposed in the search space. The problem was formulated as a two-objective optimisation problem, where they simultaneously maximise the evolved solutions regarding the Tanimoto similarity Bajusz et al. (2015) between the candidate molecule and two compounds representative of different chemical classes. The authors performed two experiments: one using two similar molecules and another using two diverse molecules. The results demonstrated that the graph-based CoG could generate a set of novel molecules that are visibly similar to the target compounds in both experiments.

Another graph-based framework, MEGA Nicolaou et al. (2009), tested the creation of new selective estrogen receptor (ER) compounds, aiming to maximise the docking score for the "positive" target receptor ER- β and minimise scores for the "negative" but closely related target ER- α . To generate molecules with desired chemical profiles similar to the known ligand tamoxifen, they used filters based on the Rule-of-Five (Ro5) and Tanimoto similarity scores as constraints. The authors pointed out the uneven nature of the objectives, *i.e.*, identifying solutions with reduced binding affinity for ER- α is substantially simpler than designing compounds with increased binding affinity for ER- β . This may lead to intense search space exploration towards the "easier" objective. To circumvent this situation, a mechanism called *niching* was used to preserve the diversity of the molecules, ensuring that the objectives were treated equally and there were no dominance conditions in favour of a specific objective. In addition, they applied *Pareto-elitism* to prevent good solutions from being "lost" during the generations. The authors reported that both mechanisms allowed the generation of many non-dominated solutions while increasing the PF extension.

In Daeyaert and Deem (2017), synthesizable molecules were generated using a GA named Synopsis Vinkers et al. (2003). The authors proposed an improved version of the *de novo* program Synopsis that incorporates the non-dominated sorting procedure from NSGAII Deb et al. (2002). The proposed algorithm was evaluated to optimise two objectives: the docking scores, computed by the Autodock Vina program Trott and Olson (2010), associated with the fibroblast growth factor (FGFR) and the vascular endothelial growth factor (VEGFR), aiming to generate dual selective inhibitors for cancer. Moreover, thirteen additional scores were used as constraints to avoid generating unwanted molecules. The obtained solutions exhibit good predicted binding energies to their targets and possess structural and physicochemical parameters falling within the typical range for drug-like molecules. The use of the Pareto dominance approach enabled the generation of high-affinity compounds within the imposed restrictions, unlike the aggregated single-objective approach, which rarely produces good-quality solutions.

In the works of Devi et al. (2019, 2020), two multi-objective methods were explored for dnDD of new drug-like molecules: the monkey algorithm (MoMADrug) Devi et al. (2019) and the biofilm algorithm (MoBifi) Devi et al. (2020). MoMADrug is inspired by the behaviour of monkeys, while MoBifi is inspired by the life cycle of bacteria in a biofilm. Both methods were adopted in the context of fragment-based *de novo* design and considered the Tanimoto

similarity to known compounds Brown (2009) and oral-bioavailability scores Lipinski (2004) as the objectives to be maximised. In addition to these two objectives, MOBifi also employed the Veber score Veber et al. (2002) as a third objective related to oral bioavailability. In Devi et al. (2019), the authors compared the MoMADrug against the MoGADdrug Devi et al. (2021), which uses a weighted sum of the objectives. Their results showed that MoMADrug could produce a more diverse set of solutions due to its multi-objective nature and its use of Pareto dominance criteria.

The MOBifi Devi et al. (2020) was originally evaluated in three unconstrained benchmark problems from CEC2009 Zhang et al. (2008) with three objectives against five other multi-objective methods. It was found that MOBifi is a competitive method in terms of the inverted generational distance (IGD) and the maximum spread (MS) performance metrics. The MOBifi method was applied to generate drug-like molecules based on reference anti-diabetic compounds from herbal plants. These generated molecules were further docked against the therapeutic targets tyrosine phosphatase 1B (PTP1B) and α -glucosidase (AGS) associated with the diabetes treatment. Two generated compounds exhibited docking scores similar to the reference inhibitor (rutin), indicating their potential as anti-diabetic agents. Since the fragments used in the dnDD strategy were generated from the commercially available databases Enamine and e-Lead3d, based on the predetermined coupling reactions concept Yuan et al. (2011), the designed molecules have a high probability of being successfully synthesised and purchased from the chemical vendors.

The proposed approach known as Deep Evolutionary Learning (DEL) introduced in Grantham et al. (2022) combines a deep generative model (DGM) with multi-objective evolutionary algorithms (MultiOEA) for dnDD. DEL leverages a fragment-based variational autoencoder (FragVAE) and NSGAII components, including non-domination rank and crowding distance, to design new molecules. By operating in the continuous latent representation space generated by the neural generative model, DEL avoids the limitations of a discrete structural space. The DGM is iteratively fine-tuned based on the newly generated populations of samples with better properties. The quantitative estimation of drug-likeness (QED), synthetic accessibility score (SAS), and logP were selected as objectives in DEL. Extensive validation of the approach was performed to assess its population validity, novelty, and diversity across various benchmarking sets, including those in the MOSES framework.

Based on the DEL framework, in Mukaidaisi et al. (2022), a graph-based DGM, called JTVAE (Junction Tree Variational AutoEncoder), is integrated into DEL to provide a latent representation space for the MultiOEA exploration. Unlike FragVAE, which utilises SMILES fragmentation, the JTVAE employs graph fragmentation following the subgraph-by-subgraph strategy. Binding affinity score (BAS) predicted with the docking program QVina, SAS, and logP of the generated molecules are the three objectives to be optimised. During the optimisation process, non-dominated ranking is performed. The VAE model is refined by selecting the high-quality generated molecules possessing significant BAS, SAS, and logP properties for the next generation. Computational experiments were conducted comparing DEL+FragVAE with the JTVAE approach on the ZINC dataset and on a variant of ZINC that included drug molecules from the DrugBank database (ZINC+DrugBank dataset). The results demonstrated that both methods improved the properties of the molecules along the generations and that the JTVAE has a higher HV value than FragVAE. These experimental results confirm that the JTVAE approach, when compared to the FragVAE approach, improves the properties of molecules during the optimization process and leads to a higher HV value.

The DrugEx is a ligand-based approach that applies RNN-based reinforcement learning to generate new chemical structures in the SMILES format. The first version of DrugEx Liu et al. (2019b) was designed to generate ligands by performing single-objective optimization using the predicted affinity against the human adenosine A_{2A} receptor as the objective through a random forest-based quantitative structure-activity relationship (QSAR) model.

In the second version, DrugEx v2 Liu et al. (2021) expanded its usage to include multi-objective optimisation by applying the concept of mutation and crossover into the Reinforcement Learning (RL) framework and a Pareto ranking procedure to handle the different objectives. The performance of DrugEx v2 was compared to ORGANIC Sanchez-Lengeling et al. (2017) and REINVENT Olivecrona et al. (2017) methods by considering as objectives the affinity prediction against either multiple targets or a single target while considering off-target effects. For multiple targets, the desired molecules should exhibit a high affinity towards A_1A and $A_{2A}A$ receptors. In contrast, in the target-specific scenario, the designed molecules should display high affinity towards A_{2A} while maintaining low affinity to A_1 . In addition, low affinity to the hERG channel (Ether-à-gogo-Related Gene, the α subunit of a potassium ion channel) is required in both cases. The generated molecules showed a large percentage of validity, low duplication, and similarity to known ligands.

In the latest version, DrugEx v3 Liu et al. (2023) adopted a graph-based transformer model as the generative model, considering user-defined scaffolds as inputs to create new molecules with desired chemical profiles. A novel encoding scheme for atoms and bonds was proposed based on an adjacency matrix to enable the transformer model to handle molecular graph representations. Unlike the previous versions, DrugEX v3 was evaluated considering two objectives: (i) the drug-likeness using the QED score and (ii) the affinity score towards the A2A receptor predicted with the random forest-based QSAR model. A Pareto-based ranking scheme was employed to rank molecules based on the average Tanimoto distance instead of the commonly employed crowding distance. SMILES and graph representations were

tested on four deep learning (DL) architectures. According to the results, all the molecules generated by the newly proposed method using the provided scaffolds were valid, and most exhibited a high predicted affinity towards A_{2A} .

5.2 ManyOO Methods: dealing with more than three objectives

5.2.1 Aggregation-based

In a recent study, Elend et al. (2022) enhanced a Pareto-based ManyOEA proposed in Cofala et al. (2020) by incorporating a neural language model trained on the ZINC database to improve the quality of generated molecules. The goal was to generate molecules that inhibit the therapeutic target Mpro of SARS-CoV-2 by considering multiple objectives such as predicted binding affinity (BA), quantitative estimate of drug-likeness (QED), natural product-likeness (NP), toxicity filter (TF), and synthetic accessibility (SA). A weighted sum approach was used to aggregate the objective values in which weights were set *a priori*. The proposed Evolutionary Molecular Generation Algorithm (EMGA) designed new molecules based on the SMILES representation. The transformer architecture in the neural language model was used as a mutation operator to generate molecule fragments, while a $(\mu + \lambda)$ Evolutionary Strategy (ES) was employed to perform a randomised search in the molecular structure search space. From the molecules generated by EMGA, twenty-one chemically valid molecules were selected for molecular dynamic (MD) simulations. Among them, two were identified as stable and had the potential to inhibit Mpro.

The ATOM Generative Molecular Design (ATOM GMD) proposed in McLoughlin et al. (2023) involves a two-stage process of a variational autoencoder (VAE) and a many-objective GA operating in the latent space. The VAE is used to map molecular structures to the continuous latent space. Specifically, a JTVAE maps a population of structures to a learned continuous latent space. The encoder component of the JTVAE converts each SMILES structure into a continuous latent vector, and the decoder component performs the opposite transformation. The GA-based approach searches for optimal molecules in the latent space, employing crossover and mutation operations to generate new molecules with desirable properties. The cost function of this ManyOO approach is a weighted sum of terms based on 12 predicted properties, including efficacy and safety (binding affinities against the therapeutic target histamine H1 receptor and the off-targets M2 and hERG predicted with QSAR models), pharmacokinetic profile (Ro5), and developability properties (SAS). The weights are set a priori. Focusing on developing potent and selective H1 antagonists, the ATOM GMD approach generated several molecules, of which 106 compounds were further synthesised and experimentally evaluated. Six tested compounds were found to bind H1 at nanomolar concentrations selectively. During the training, the authors included molecules from Neurocrine Biosciences, ChEMBL, and GoStar with known affinity against H1 and compounds structurally similar to the known H1 antagonists from the Enamine REAL Space. This was done to bias the generation of new structures towards the desired profile. Despite being a preprint at the time of our review, to the best of our knowledge, this is the first published work that successfully applied ManyOO, EAs, and ML methods with experimental validation. This highlights the powerful application of Multi/ManyOO strategies in the context of dnDD.

5.2.2 Pareto-based

Recently, Verhellen (2022) evaluated the performance of graph-based implementations of NSGA-II and NSGA-III against a weighted sum method on case studies from the GuacaMol benchmark suite for dnDD Brown et al. (2019) and from datasets constructed to simulate polypharmacology scenarios. The number of optimised objectives ranged from four to five, depending on the benchmark molecule analysed, including molecular weight, logP, similarity, affinity to a target, and/or blood–brain–barrier permeability. The optimisation procedure removed undesired molecules from the population based on structural ADMET filters. Both approaches outperform the weighted sum method in terms of the HV indicator. Regarding efficiency, NSGA-III outperformed NSGA-II by performing fewer function evaluations in all benchmarks. However, both approaches showed similar performance on the analysed chemical benchmarks. By conducting this comparison, the authors provided valuable insights for effectively applying Multi/ManyOO approaches in dnDD.

Molecules for anti-breast cancer were produced in Mei and Wu (2022) using an enhanced ManyOEA variant, AGM-MOEA Panichella (2019). The proposed method applies the crossover operator from Differential Evolution Price et al. (2005), non-dominated sorting from NSGA-II Deb et al. (2002) and a normalisation method from NSGA-III Deb and Jain (2014) for generating and selecting molecules. Six objectives were simultaneously optimized: pIC₅₀ and ADMET properties (Caco-2, CYP3 A4, hERG, HOB, MN), and three performance metrics measured the quality of the PF obtained. To highlight the importance of adopting a ManyOO approach, the authors demonstrated the conflicting nature of the objectives and emphasised that a simple aggregation of the objectives could be a difficult task. A comparative analysis was conducted between the proposed framework and three other methods: NSGA-II, NSGA-III and the original AGE-MOEA. The results indicated the superiority of the proposed method regarding the performance metrics.

The design of an inhibitor for SARS-CoV-2's main protease was proposed by Cofala et al. (2020). Their proposed method combined a $(\mu + \lambda)$ ES and an NSGA-II-based method. The ManyOEA proposed uses the SELFIES representation for designing new molecules. Five molecular properties were used in the optimisation process: binding affinity (BA) computed by the QuickVina2 binding scoring function, QED, SAS, natural product-likeness (NP), and medical chemical filters (MC). Two experiments used the N3 inhibitor and lopinavir, an HIV main protease inhibitor, as ligands targeting the main protease Mpro receptor. First, a SingleOO experiment was conducted, where the fitness function was composed of a weighted sum of the five properties. In preliminary experiments, the authors observed that (i) molecules with high binding scores suffer from low QED scores, and (ii) defining the weights for the objectives could be difficult, concluding that a many-objective approach might be more appropriate. Hence, a many-objective analysis was also conducted, in which the HV metric was used to evaluate the final set of solutions. For the SingleOO experiment, the authors highlighted the conflicting nature of the objectives, which resulted in a trade-off between QED and NP scores versus SA and BA scores. Even so, according to the binding scores, the best molecule found in the SingleOO approach achieved better scores than those of N3 and lopinavir. On the other hand, the ManyOO provided a higher diversity of molecules when compared with the SingleOO case, achieving satisfactory values for all properties.

A Generative Adversarial Network (GAN), proposed by Abbasi et al. (2022), combines an autoencoder with a GAN to convert SMILES strings into latent space vectors and use them as real data in GAN training. To generate molecules that exhibit multiple desired properties, an optimisation step based on feedbackGAN Gupta and Zou (2019) is applied, incorporating the NSGA-II method to generate non-dominated solutions that will be included in the training set. The case study analysed aimed to find ligands that bind both to the Kappa Opioid Receptor (KOR) and the A2A receptor (ADORA2A). The other properties to be optimised include the binding affinity pIC50, the molecular topological polar surface area (TPSA), the solubility (LogP) and the SAS. The strategy adopted was evaluated based on several metrics, such as validity, uniqueness and novelty. The proposed framework generated molecules with a high level of diversity (over 0.88) and 100% uniqueness but a low percentage of validly generated molecules (30.2%).

5.3 Objectives or constraints?

In implementing different dnDD strategies, a very important aspect is determining which of the desired properties should be considered as objectives or constraints. Nicolaou et al. (2009) classified their objectives as primary (objectives used to guide the search procedure) and secondary (objectives acting as constraints that can be used as filters to restrict the search space). Properties serving as objectives are typically related to the similarity to a known ligand (e.g. Tanimoto similarity) or binding affinity scores with one or more receptor target(s) of interest. Constraints usually involve descriptors related to pharmacokinetic prediction (e.g. Lipinski's Ro5) and synthetic accessibility. However, it is important to highlight that the researchers define the premises of development, not existing a rule to state which properties must be defined as an objective or a constraint.

Binding affinity scores are widely used as an objective in the optimisation procedure to consider the potency of a compound against the therapeutic targets of interest. However, ignoring other information (objectives) important for a drug to pass clinical trials and reach the market can affect the quality of the designed molecules Fu et al. (2022). In this way, several works include other properties in a Multi/ManyOO context, such as QED, logP and SAS.

As previously mentioned, when the number of objectives increases (>3), the number of Pareto-optimal solutions becomes intractable. Hence, in selecting the number of objectives, the researchers must also consider this issue when choosing an appropriate technique to deal with the different objectives and constraints. To alleviate this drawback, in Daeyaert and Deem (2017), it was proposed to define some objectives as constraints so that the dimension of the problem could be restricted to two or three objectives, allowing the application of MultiOEAs as the search procedure. On the other hand, many works adopted a scalarization procedure to aggregate the many objectives into one, using an *a prior* optimisation method, thus transforming a multi-objective problem into a single-objective optimisation process. In both approaches, detailed knowledge of the problem is required to define the most suitable properties that should be used as objectives or to set the weight vectors to obtain a Pareto-optimal solution (hopefully) in a desired region of the objective space.

It is also crucial to avoid the use of redundant objectives that would increase the complexity of the problem without providing a real increase in accuracy. For example, in the MOBifi Devi et al. (2020), they adopted two correlated objectives for drug-likeness (Veber and Lipinski's rules). Although these metrics are based on different parameters, Veber's rules are claimed to improve Lipinski's rule, probably discarding the necessity of considering both approaches simultaneously in the MultiOO context. Thus, the selection of the objectives can also be guided by dimensionality reduction methods to reduce the number of effective objectives.

EAs are originally unconstrained search techniques, requiring additional mechanisms to deal with constraints. A simple approach is to discard unwanted solutions during the search process. However, this strategy may not be adequate since

the usual assumption is that the first generations of EAs may contain diverse infeasible but still promising solutions. Some examples of alternative approaches to deal with constraints include Mezura-Montes and Coello (2011); Rahimi et al. (2023):

- penalty functions to add a penalty value to the objective function for infeasible solutions;
- move operators and special representation schemes that guarantee the generation of feasible solutions;
- repair techniques to move unfeasible points back to the feasible space;
- feasibility rules for selecting feasible and infeasible individuals; and
- hybrid approaches that combine different strategies to treat constraints

Among those techniques, special move operators and repair techniques are used mainly to guarantee the generation of feasible solutions. For instance, the GANDI Dey and Caffisch (2008) methodology enforces feasibility by forbidding certain connections on the molecule. CoG Brown et al. (2004) applies special mutation and crossover operations on the graph representation. Synopsis Daeyaert and Deem (2017) enforces feasibility rules in which constraint violations are considered for selecting a new compound. Invalid and toxic molecules are discarded in DEL Grantham et al. (2022) and during the optimisation process of EMOA Cofala et al. (2020). A repair mechanism is used in DrugEx v3 Liu et al. (2023) to correct chemically invalid molecules.

Recently, a helpful tool proposed by Schoenmaker et al. (2023) for molecular correction through a generative deep learning method could be used as a repair technique to correct invalid but interesting compounds.

Table 1 summarises the multi-objective and many-objective techniques cited in the previous sections, including their choice of objectives and constraints, the constraint handling techniques applied, and the Multi/ManyOO approach adopted.

It is important to highlight that even considering only objectives, such as machine learning predicted binding affinities, related to diverse targets through many-objectives methodologies in dnDD could *per se* provide a robust framework for designing and optimising more effective drug candidates. In fact, there is a crescent interest in the development of new compounds targeting multiple targets in a polypharmacology context (*on*-targets), for example, to reduce bacterial resistance, whereas avoiding the interaction with receptors related to side effects (*off*-targets) Zięba et al. (2022); Raghavendra et al. (2018); Wang et al. (2021); Dias et al. (2017). Furthermore, by incorporating diverse objectives and constraints related to potency, selectivity, and pharmacokinetics, ManyOO methodologies might enable the design of compounds that exhibit improved overall performance and a higher probability of success in clinical trials.

Table 1: Multi-objective and many-objective methods for de novo drug design.

Method	Molecular Generation	Objectives	Constraints	Constraints Handling Technique	Multi/ManyOO Approach (final result)	REF.
Multi-objective methods	spor					
GANDI	GA^b and TS^b	Force field-based binding energy and 2D/3D similarity measure to a known ligand	Chemical validity	Special move operators and elimination of compounds with steric clashes	Aggregation-based (single solution)	Dey and Caffisch (2008)
MOGA	GA^{b}	Oral bio-availability and Tanimoto similarity with known ligands	Synthetic accessibility	Special move operators	Aggregation-based (single solution)	Devi et al. (2014)
MoGADdrug	GA^b	Oral bio-availability and Tanimoto similarity with known Igands	Synthetic accessibility	Special move operators	Aggregation-based (single solution)	Devi et al. (2021)
CoG	GP^{b}	Tanimoto similarity between two compounds	Chemical validity	Special move operators	Pareto-based	Brown et al. (2004)
MEGA	$GA ext{-}based^b$	Docking score against multiple targets	Tanimoto similarity with known ligands and Ro5	Special move operators	Pareto-based	Nicolaou et al. (2009)
Synopsis	GA^{b}	Docking score against multiple targets	RotB, longest sp3-sp3 chain, reactive groups, volume, logP, PSA, molar refractivity, interaction with specific regions of the targets (hinge, backbrocket, hydrophobic)	Feasibility rules	Pareto-based	Daeyaert and Deem (2017)
MoMADrug MOBifi	Monkey Algorithm Biofilm Algorithm	Tanimoto similarity with known ligands and Ro5 Tanimoto similarity with known ligands, Ro5 and Veber rules			Pareto-based Pareto-based	Devi et al. (2019) Devi et al. (2020)
DEL	DGM^b (VAE)	QED^a , SAS^a and logP	Chemical validity	Elimination of invalid and duplicated SMILES strings	Pareto-based	Grantham et al. (2022)
DEL-based	DGM ^b (JTVAE)	Affinity prediction, SAS^a and $logP$	Chemical validity	Elimination of invalid and duplicated SMILES strings	Pareto-based	Mukaidaisi et al. (2022)
DrugEx v2	DRL^b	Affinity prediction towards two targets and one off-target		1	Pareto-based	Liu et al. (2021)
DrugEx v3 Gr Many-objective methods	Graph Tansformer hods	QED ^a and affinity prediction to a pre-defined receptor	Chemical validity	Repair technique	Pareto-based	Liu et al. (2023)
EMGA	NLM^b (Transformer)	Predicted affinity , QED^{α} , natural product-likeness, toxicity scores and synthetic accessibility			Aggregation-based (single solution)	Elend et al. (2022)
ATOM-GMD	DGM ^b (JTVAE)	12 predicted properties, including terms related to efficacy and safety (on and off-target affinities predicted with QSAR models), Ro5 and accessibility scores	,		Aggregation-based (non-dominated solutions)	McLoughlin et al. (2023)
NSGAII and NSGAIII-based	$\mathrm{GA} ext{-}\mathrm{based}^b$	Ranged from four to five (molecular weight, logp, similarity, affinity prediction to a target of interest, and/or blood-brain-barrier permeability)	ADMET filters	Elimination of undesirable compounds	Pareto-based	Verhellen (2022)
AGM-MOEA	$\mathrm{EA} ext{-}\mathrm{based}^b$	Affinity prediction and ADMET properties (Caco-2, CYP3 A4, hERG, HOB, MN)			Pareto-based	Mei and Wu (2022)
EMOA	$EA ext{-}based^b$	Affinity prediction , QED a , natural product-likeness, toxicity scores and SAS a	Toxicity filters	Elimination of toxic molecules	Pareto-based	Cofala et al. (2020)
GAN-based	${ m GAN}^b$	Affinity prediction, topological polar surface area (TPSA), LogP and $SAS^{\it cl}$			Pareto-based	Abbasi et al. (2022)

^a Quantitative estimation of drug-likeness (QED); Synthetic accessibility score (SAS).

^b Genetic Algorithm (GA); Tabu Search (TS); Genetic Programming (GP); Evolutionary Algorithm (EA); Deep Generative Model (DGM); Generative Adversarial Network (GAN); Deep Reinforcement Learning (DRL); Neural Language Model (NLM).

6 Discussion

The application of multi-objective techniques has become well-established in the field of dnDD. This strategy improves the solutions' quality by considering multiple objectives simultaneously, leading to a more realistic representation of the problem. It is worth noting that a few papers Luukkonen et al. (2023); Liu et al. (2021) emphasise the importance of addressing problems with more than three objectives in diverse areas. However, the proper exploration of ManyOO approaches in dnDD is still scarce despite its significant potential.

The issue of dimensionality in dnDD has been recognised by researchers as an important topic that needs consideration Nicolaou et al. (2009); Devi et al. (2014); Grantham et al. (2022). Despite the use of ManyOEAs in Mei and Wu (2022); Verhellen (2022), none of these papers explicitly address the significantly more complex and challenging nature of problems that arise when dealing with more than three objectives. It is relevant to observe that in Cofala et al. (2020), five objectives are employed in the optimisation process using the NSGA-II method, a MultiOEA more suitable for handling problems with up to three objectives. As previously mentioned, NSGA-II encounters additional difficulties as the number of objectives increases. In such scenarios, NSGA-III or other ManyOEAs could be more appropriate alternatives for handling the problem. Hence, it is important to highlight the following reflections.

- 1. ManyOO methods still haven't received enough attention from the dnDD community. Among all the papers cited herein, only a few of them Elend et al. (2022); McLoughlin et al. (2023); Verhellen (2022); Mei and Wu (2022); Cofala et al. (2020) simultaneously optimised more than three objectives. One is a preprint, and the others were recently published. Although dnDD research has increased rapidly over the years, its application to the many-objective case seems recent.
- 2. Although in those papers ManyOEAs were used, rarely is there an emphasis on the fact that they are dealing with a much more complex and challenging class of problems compared to cases with up to three objectives.
- 3. We observed that many papers adopt aggregation-based techniques, most of which apply the weighted sum aggregation approach. It is important to note that other aggregation-based techniques are more efficient and equally simple to implement. The assumption that the optimisation problems are always convex to justify the efficient use of weighted sum aggregation is not always valid in a complex and challenging problem such as the dnDD.
- 4. Some papers considered multi-target evaluations in the context of polypharmacology and/or off-targets, but they are often limited to two or three targets simultaneously. However, there are important contexts in which binding affinity against multiple targets could be considered at the same time, for example, when developing new compounds against infectious diseases (multiple targets for the same pathogen could improve drug efficacy) or in the case of kinase inhibitors (off-targets panel containing dozens of kinases to evaluate selectivity).

Aggregation-based and weight-based approaches are widely used because they simplify the problem by reducing its dimensionality. However, it is important to highlight that methods based on *a priori* aggregation provide only one solution among the several possibilities of existing non-dominated solutions. As stated earlier, using aggregating techniques is the easiest way to approach the problem, but it oversimplifies and fails to inform the user about the trade-offs between the objectives. Besides, with the increase in the number and diversity of objectives, choosing and normalizing weight vectors becomes progressively difficult. Thus, to overcome these issues and take advantage of a more diverse set of non-dominated solutions, we believe many-objective Pareto-based approaches will increase prevalence in dnDD and be the centre of novel methodological developments. We also are convinced that, given its intrinsic attributes — namely, the quantity and variety of objectives and constraints, along with the diversity of possible approaches in their prioritisation — many-objective dnDD optimisation might indeed serve as a source of inspiration for new developments in more fundamental and general methodological frameworks within the field of ManyOO.

Although this paper does not focus on machine learning (ML) techniques, it is important to mention that recent papers have demonstrated a notable increase in the number of works incorporating ML techniques and evolutionary computing algorithms and concepts in their models, particularly in generative models. For those interested in this field, comprehensive reviews of ML techniques for dnDD can be found in Mouchlis et al. (2021); Bilodeau et al. (2022); Wang et al. (2022); Luukkonen et al. (2023). While few of them briefly mention papers exploring MultiOO, with the majority utilising MultiOEAs, only the recently published paper Luukkonen et al. (2023) gives special attention to ML methods for multi-objective dnDD. They also list multi-objective ML-based methods, including EAs, reinforcement/conditional learning, and recurrent neural networks. We believe new developments involving ML techniques and ManyOEAs should generate powerful tools for dealing with dnDD.

7 Conclusions

This work presented an overview of MultiOO and ManyOO approaches applied in dnDD, particularly those based on evolutionary computation and machine learning techniques. We provide a general review of the definitions involved in MultiOOPs and ManyOOPs, emphasising the main challenges that appear when the number of objectives of an optimisation problem increases. Our review could trace possible improvements and drawbacks in designing new optimisation techniques by examining how the molecular properties are utilised in the dnDD problem to define objectives and constraints. The increasing interest in applying ManyOO in dnDD is evident, in which evolutionary computation, coupled with ML methods, has continuously strengthened. Those approaches evolve toward efficiently solving the dnDD problem regarding the number of objectives and/or constraints considered. Still, given the multitude and diverse dnDD's characteristics as a ManyOO process, it may serve as a catalyst for new developments in more fundamental and general methodological frameworks within the ManyOO field.

Finally, integrating multi-target drug development and many-objectives optimisation approaches has great potential for accelerating the discovery of innovative and more efficacious drug therapies.

Acknowledgement

This work was supported by the Brazilian agencies Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) [grant numbers 301524/2023-8, 309744/2022-9]; and the Fundação Carlos Chagas Filho de Apoio à Ciência (FAPERJ) [grant numbers E-26/010.001415/2019, E-26/211.357/2021, E-26/200.393/2023, E-26/200.608/2022, E-26/210.372/2022].

Declaration of Generative AI and AI-assisted technologies in the writing process

During the preparation of this work, the authors used ChatGPT and Grammarly to improve readability and language. After using these tools/services, the authors reviewed and edited the content as needed and took full responsibility for the content of the publication.

References

- Abbasi, M., Santos, B. P., Pereira, T. C., Sofia, R., Monteiro, N. R. C., Simões, C. J. V., Brito, R. M. M., Ribeiro, B., Oliveira, J. L., and Arrais, J. P. (2022). Designing optimized drug candidates with generative adversarial network. *Journal of Cheminformatics*, 14(1):40.
- Allmendinger, R., Jaszkiewicz, A., Liefooghe, A., and Tammer, C. (2022). What if we increase the number of objectives? Theoretical and empirical implications for many-objective combinatorial optimization. *Computers & Operations Research*, 145:105857.
- Asafuddoula, M., Ray, T., and Sarker, R. (2015). A decomposition-based evolutionary algorithm for many objective optimization. *IEEE Trans. on Evolutionary Computation*, 19(3):445–460.
- Bader, J., Deb, K., and Zitzler, E. (2010). Faster hypervolume-based search using Monte Carlo sampling. In Ehrgott, M., Naujoks, B., Stewart, T. J., and Wallenius, J., editors, *Multiple Criteria Decision Making for Sustainable Energy and Transportation Systems*, pages 313–326, Berlin, Heidelberg. Springer Berlin Heidelberg.
- Bader, J. and Zitzler, E. (2011). HypE: An algorithm for fast hypervolume-based many-objective optimization. *Evolutionary Computation*, 19(1):45–76.
- Bajusz, D., Rácz, A., and Héberger, K. (2015). Why is tanimoto index an appropriate choice for fingerprint-based similarity calculations? *Journal of Cheminformatics*, 7.
- Batista, L. S., Campelo, F., Guimarães, F. G., and Ramírez, J. A. (2011). Pareto cone *ϵ*-dominance: Improving convergence and diversity in multiobjective evolutionary algorithms. In Takahashi, R. H. C., Deb, K., Wanner, E. F., and Greco, S., editors, *Evolutionary Multi-Criterion Optimization*, pages 76–90. Springer Berlin Heidelberg.
- Ben Amor, O., Chelly Dagdia, Z., Bechikh, S., and Ben Said, L. (2022). Many-objective optimization of wireless sensor network deployment. *Evolutionary Intelligence*.
- Beume, N., Fonseca, C. M., López-Ibáñez, M., Paquete, L., and Vahrenhold, J. (2009). On the complexity of computing the hypervolume indicator. *IEEE Trans. Evol. Comp.*, 13(5):1075–1082.
- Bilodeau, C., Jin, W., Jaakkola, T., Barzilay, R., and Jensen, K. F. (2022). Generative models for molecular discovery: Recent advances and challenges. *WIREs Computational Molecular Science*, 12(5):e1608.

- Branke, J., Deb, K., Miettinen, K., and Slowinski, R., editors (2008). *Multiobjective Optimization: Interactive and Evolutionary Approaches*. Springer.
- Brockhoff, D. and Zitzler, E. (2006). Are all objectives necessary? On dimensionality reduction in evolutionary multiobjective optimization. In Runarsson, T. P., Beyer, H.-G., Burke, E., Merelo-uervós, J. J., Whitley, L. D., and Yao, X., editors, *Parallel Problem Solving from Nature PPSN IX*, pages 533–542, Berlin, Heidelberg. Springer Berlin Heidelberg.
- Brockhoff, D. and Zitzler, E. (2007). Dimensionality reduction in multiobjective optimization: The minimum objective subset problem. In Waldmann, K.-H. and Stocker, U. M., editors, *Operations Research Proceedings* 2006, pages 423–429, Berlin, Heidelberg. Springer Berlin Heidelberg.
- Brown, N. (2009). Chemoinformatics An introduction for Computer Scientists. ACM Comput. Surv., 41(2).
- Brown, N., Fiscato, M., Segler, M. H., and Vaucher, A. C. (2019). Guacamol: Benchmarking models for de novo molecular design. *Journal of Chemical Information and Modeling*, 59(3):1096–1108. PMID: 30887799.
- Brown, N., McKay, B., Gilardoni, F., and Gasteiger, J. (2004). A graph-based genetic algorithm and its application to the multiobjective evolution of median molecules. *Journal of Chemical Information and Computer Sciences*, 44(3):1079–1087.
- Coello, C. A. C., Lamont, G. B., and Veldhuizen, D. A. V. (2007). *Evolutionary Algorithms for Solving Multi-Objective Problems*. Springer New York, NY.
- Cofala, T., Elend, L., Mirbach, P., Prellberg, J., Teusch, T., and Kramer, O. (2020). Evolutionary multi-objective design of sars-cov-2 protease inhibitor candidates. In Bäck, T., Preuss, M., Deutz, A., Wang, H., Doerr, C., Emmerich, M., and Trautmann, H., editors, *Parallel Problem Solving from Nature PPSN XVI*, pages 357–371, Cham. Springer International Publishing.
- Daeyaert, F. and Deem, M. W. (2017). A pareto algorithm for efficient de novo design of multi-functional molecules. *Molecular Informatics*, 36(1-2):1600044.
- Dai, C., Wang, Y., and Ye, M. (2014). A new evolutionary algorithm based on contraction method for many-objective optimization problems. *Applied Mathematics and Computation*, 245:191–205.
- de Farias, L. R. and Araújo, A. F. (2022). A decomposition-based many-objective evolutionary algorithm updating weights when required. *Swarm and Evolutionary Computation*, 68:100980.
- de Freitas, A. R., Fleming, P. J., and Guimarães, F. G. (2015). Aggregation trees for visualization and dimension reduction in many-objective optimization. *Information Sciences*, 298:288–314.
- Deb, K. (2001). Multi-Objective Optimization using Evolutionary Algorithms. John Wiley & Sons.
- Deb, K., Fleming, P., Jin, Y., Miettinen, K., and Reed, P. M. (2023). *Key Issues in Real-World Applications of Many-Objective Optimisation and Decision Analysis*, pages 29–57. Springer International Publishing, Cham.
- Deb, K., Gupta, S., Daum, D., Branke, J., Mall, A. K., and Padmanabhan, D. (2009). Reliability-based optimization using evolutionary algorithms. *IEEE Trans. on Evolutionary Computation*, 13(5):1054–1074.
- Deb, K. and Jain, H. (2014). An evolutionary many-objective optimization algorithm using reference-point-based nondominated sorting approach, part i: Solving problems with box constraints. *IEEE Trans. on Evolutionary Computation*, 18(4):577–601.
- Deb, K., Pratap, A., Agarwal, S., and Meyarivan, T. (2002). A fast and elitist multiobjective genetic algorithm: NSGA-II. *IEEE Trans. on Evolutionary Computation*, 6(2):182–197.
- Deb, K. and Sundar, J. (2006). Reference point based multi-objective optimization using evolutionary algorithms. In *Proceedings of the 8th Annual Conference on Genetic and Evolutionary Computation*, GECCO '06, page 635–642, New York, NY, USA. Association for Computing Machinery.
- Devi, R., Sathya, S., Kumar, N., and Coumar, M. (2019). Multi-objective monkey algorithm for drug design. *Intl. Journal of Intelligent Systems and Applications*, 3:31–41.
- Devi, R. V., Sathya, S. S., and Coumar, M. S. (2014). Multi-objective genetic algorithm for de novo drug design. *International Journal of Soft Computing and Engineering (IJSCE)*, 4(2):92–96.
- Devi, R. V., Sathya, S. S., and Coumar, M. S. (2015). Evolutionary algorithms for de novo drug design A survey. *Applied Soft Computing*, 27:543–552.
- Devi, R. V., Siva Sathya, S., and Coumar, M. S. (2020). Multi-objective biofilm algorithm (mobifi) for de novo drug design with special focus to anti-diabetic drugs. *Applied Soft Computing*, 96:106655.
- Devi, V. R., Sathya, S. S., and Coumar, S. M. (2021). Multi-objective genetic algorithm for de novo drug design (MoGADdrug). *Current Computer-Aided Drug Design*, 17(3):445–457.

- Dey, F. and Caflisch, A. (2008). Fragment-based de novo ligand design by multiobjective evolutionary optimization. *Journal of Chemical Information and Modeling*, 48(3):679–690. PMID: 18307332.
- Dias, K. S. T., de Paula, C. T., dos Santos, T., Souza, I. N., Boni, M. S., Guimarães, M. J., da Silva, F. M., Castro, N. G., Neves, G. A., Veloso, C. C., Coelho, M. M., de Melo, I. S. F., Giusti, F. C., Giusti-Paiva, A., da Silva, M. L., Dardenne, L. E., Guedes, I. A., Pruccoli, L., Morroni, F., Tarozzi, A., and Viegas, C. (2017). Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multitarget drugs for the treatment of alzheimer's disease. *European Journal of Medicinal Chemistry*, 130:440–457.
- Ekins, S., Honeycutt, J. D., and Metz, J. T. (2010). Evolving molecules using multi-objective optimization: applying to ADME/Tox. *Drug Discovery Today*, 15(11):451–460.
- Elend, L., Jacobsen, L., Cofala, T., Prellberg, J., Teusch, T., Kramer, O., and Solov'yov, I. A. (2022). Design of sars-cov-2 main protease inhibitors using artificial intelligence and molecular dynamic simulations. *Molecules*, 27(13).
- Emmerich, M. T. M. and Deutz, A. H. (2018). A tutorial on multiobjective optimization: fundamentals and evolutionary methods. *Natural Computing*, 17(3):585–606.
- Erickson, M., Mayer, A., and Horn, J. (2001). The Niched Pareto Genetic Algorithm 2 applied to the design of groundwater remediation systems. In Zitzler, E., Thiele, L., Deb, K., Coello Coello, C. A., and Corne, D., editors, *Evolutionary Multi-Criterion Optimization*, pages 681–695. Springer Berlin Heidelberg.
- Falcón-Cardona, J. G. and Coello, C. A. C. (2020a). Indicator-based multi-objective evolutionary algorithms: A comprehensive survey. *ACM Comput. Surv.*, 53(2).
- Falcón-Cardona, J. G. and Coello, C. A. C. (2020b). Indicator-based multi-objective evolutionary algorithms: A comprehensive survey. *ACM Comput. Surv.*, 53(2).
- Fu, T., Gao, W., Coley, C. W., and Sun, J. (2022). Reinforced genetic algorithm for structure-based drug design. In *39th International Conference on Machine Learning (ICML)*, page 1.
- Glover, F. and Laguna, M. (1997). Tabu Search. Springer New York, NY.
- Grantham, K., Mukaidaisi, M., Ooi, H. K., Ghaemi, M. S., Tchagang, A., and Li, Y. (2022). Deep evolutionary learning for molecular design. *IEEE Computational Intelligence Magazine*, 17(2):14–28.
- Guedes, I. A., Barreto, A. M. S., Marinho, D., Krempser, E., Kuenemann, M. A., Sperandio, O., Dardenne, L. E., and Miteva, M. A. (2021). New machine learning and physics-based scoring functions for drug discovery. *Scientific Reports*, 11(1):3198.
- Guerreiro, A. P. and Fonseca, C. M. (2018). Computing and updating hypervolume contributions in up to four dimensions. *IEEE Trans. on Evolutionary Computation*, 22(3):449–463.
- Gupta, A. and Zou, J. (2019). Feedback gan for dna optimizes protein functions. *Nature Machine Intelligence*, 1(2):105–111.
- Handl, J., Kell, D. B., and Knowles, J. (2007). Multiobjective optimization in bioinformatics and computational biology. *IEEE/ACM Transactions on Computational Biology and Bioinformatics*, 4(2):279–292.
- Holland, J. H. (1962). Outline for a logical theory of adaptive systems. J. ACM, 9(3):297-314.
- Holland, J. H. (1975). Adaptation in Natural and Artificial Systems. The University of Michigan Press.
- Horn, J., Nafpliotis, N., and Goldberg, D. (1994). A niched Pareto genetic algorithm for multiobjective optimization. In *Proc. of the First IEEE Conf. on Evolutionary Computation. IEEE World Congress on Computational Intelligence*, pages 82–87 vol.1.
- Ikeda, K., Kita, H., and Kobayashi, S. (2001). Failure of Pareto-based MOEAs: Does non-dominated really mean near to optimal? In *Proc. of the 2001 Congress on Evolutionary Computation*, volume 2, pages 957–962.
- Irwin, J. J. and Shoichet, B. K. (2005). ZINC-A free database of commercially available compounds for virtual screening. *Journal of Chemical Information and Modeling*, 45(1):177–182. PMID: 15667143.
- Ishibuchi, H., Setoguchi, Y., Masuda, H., and Nojima, Y. (2016). How to compare many-objective algorithms under different settings of population and archive sizes. In 2016 IEEE Congress on Evolutionary Computation (CEC), pages 1149–1156.
- Ishibuchi, H., Setoguchi, Y., Masuda, H., and Nojima, Y. (2017). Performance of decomposition-based many-objective algorithms strongly depends on pareto front shapes. *IEEE Transactions on Evolutionary Computation*, 21(2):169–190.
- Ishibuchi, H., Tsukamoto, N., and Nojima, Y. (2008). Evolutionary many-objective optimization: A short review. In 2008 IEEE Congress on Evolutionary Computation (IEEE World Congress on Computational Intelligence), pages 2419–2426.

- Jain, H. and Deb, K. (2014). An evolutionary many-objective optimization algorithm using reference-point based nondominated sorting approach, part ii: Handling constraints and extending to an adaptive approach. *IEEE Trans. on Evolutionary Computation*, 18(4):602–622.
- Knowles, J. D. and Corne, D. W. (1999). The Pareto archived evolution strategy: a new baseline algorithm for Pareto multiobjective optimisation. In *Proc. of the 1999 Congress on Evolutionary Computation*, volume 1, pages 98–105.
- Knowles, J. D. and Corne, D. W. (2000). Approximating the nondominated front using the Pareto archived evolution strategy. *Evolutionary Computation*, 8(2):149–172.
- Lambrinidis, G. and Tsantili-Kakoulidou, A. (2021). Multi-objective optimization methods in novel drug design. *Expert Opinion on Drug Discovery*, 16(6):647–658. PMID: 33353441.
- Laumanns, M., Thiele, L., Deb, K., and Zitzler, E. (2002). Combining convergence and diversity in evolutionary multiobjective optimization. *Evol. Comput.*, 10(3):263–282.
- Le, T. C. and Winkler, D. A. (2015). A bright future for evolutionary methods in drug design. *ChemMedChem*, 10(8):1296–1300.
- Li, B., Li, J., Tang, K., and Yao, X. (2015a). Many-objective evolutionary algorithms: A survey. *ACM Comput. Surv.*, 48(1).
- Li, K., Deb, K., Zhang, Q., and Kwong, S. (2015b). An evolutionary many-objective optimization algorithm based on dominance and decomposition. *IEEE Transactions on Evolutionary Computation*, 19(5):694–716.
- Lipinski, C. A. (2004). Lead- and drug-like compounds: the rule-of-five revolution. *Drug Discovery Today: Technologies*, 1(4):337–341.
- Liu, J., Wang, Y., Wang, X., Guo, S., and Sui, X. (2019a). A new dominance method based on expanding dominated area for many-objective optimization. *Intl. Journal of Pattern Recognition and Artificial Intelligence*, 33(03):1959008.
- Liu, X., Ye, K., van Vlijmen, H. W. T., Emmerich, M. T. M., IJzerman, A. P., and van Westen, G. J. P. (2021). Drugex v2: de novo design of drug molecules by pareto-based multi-objective reinforcement learning in polypharmacology. *Journal of Cheminformatics*, 13.
- Liu, X., Ye, K., van Vlijmen, H. W. T., IJzerman, A. P., and van Westen, G. J. P. (2019b). An exploration strategy improves the diversity of de novo ligands using deep reinforcement learning: a case for the adenosine a2a receptor. *Journal of Cheminformatics*, 11(1).
- Liu, X., Ye, K., van Vlijmen, H. W. T., IJzerman, A. P., and van Westen, G. J. P. (2023). Drugex v3: scaffold-constrained drug design with graph transformer-based reinforcement learning. *Journal of Cheminformatics*, 15(1).
- Loving, K., Alberts, I., and Sherman, W. (2010). Computational approaches for fragment-based and de novo design. *Current Topics in Medicinal Chemistry*, 10(1):14–32.
- Luukkonen, S., van den Maagdenberg, H. W., Emmerich, M. T., and van Westen, G. J. (2023). Artificial intelligence in multi-objective drug design. *Current Opinion in Structural Biology*, 79:102537.
- Mane, S. U. and Narasinga Rao, M. (2017). Many-objective optimization: Problems and evolutionary algorithms a short review. *International Journal of Applied Engineering Research*, 12(20):9774 9793. Cited by: 18.
- McLoughlin, K. S., Shi, D., Mast, J. E., Bucci, J., Williams, J. P., Jones, W. D., Miyao, D., Nam, L., Osswald, H. L., Zegelman, L., Allen, J., Bennion, B. J., Paulson, A. K., Abagyan, R., Head, M. S., and Brase, J. M. (2023). Generative molecular design and experimental validation of selective histamine h1 inhibitors. *bioRxiv*.
- Mei, Y. and Wu, K. (2022). Application of multi-objective optimization in the study of anti-breast cancer candidate drugs. *Scientific Reports*, 12(1).
- Mezura-Montes, E. and Coello, C. A. C. (2011). Constraint-handling in nature-inspired numerical optimization: Past, present and future. *Swarm and Evolutionary Computation*, 1(4):173–194.
- Miettinen, K. (1999). Nonlinear Multiobjective Optimization. Kluwer Academic, Norwell, Massachusetts.
- Mouchlis, V. D., Afantitis, A., Serra, A., Fratello, M., Papadiamantis, A. G., Aidinis, V., Lynch, I., Greco, D., and Melagraki, G. (2021). Advances in de novo drug design: From conventional to machine learning methods. *Intl. Journal of Molecular Sciences*, 22(4).
- Mukaidaisi, M., Vu, A., Grantham, K., Tchagang, A., and Li, Y. (2022). Multi-objective drug design based on graph-fragment molecular representation and deep evolutionary learning. *Frontiers in Pharmacology*, 13.
- Nicolaou, A. C. and Kannas, C. and Loizidou, E. (2012). Multi-objective optimization methods in de novo drug design. *Mini-Reviews in Medicinal Chemistry*, 12(10):979–987.

- Nicolaou, C. A., Apostolakis, J., and Pattichis, C. S. (2009). De novo drug design using multiobjective evolutionary graphs. *Journal of Chemical Information and Modeling*, 49(2):295–307. PMID: 19170611.
- Nicolotti, O., Giangreco, I., Introcaso, A., Leonetti, F., Stefanachi, A., and Carotti, A. (2011). Strategies of multi-objective optimization in drug discovery and development. *Expert Opinion on Drug Discovery*, 6(9):871–884. PMID: 22646211.
- Nishibata, Y. and Itai, A. (1991). Automatic creation of drug candidate structures based on receptor structure. starting point for artificial lead generation. *Tetrahedron*, 47(43):8985–8990.
- Olivecrona, M., Blaschke, T., Engkvist, O., and Chen, H. (2017). Molecular de-novo design through deep reinforcement learning. *Journal of Cheminformatics*, 9(1).
- Panichella, A. (2019). An adaptive evolutionary algorithm based on non-euclidean geometry for many-objective optimization. In *Proceedings of the Genetic and Evolutionary Computation Conference*, GECCO '19, page 595–603, New York, NY, USA. Association for Computing Machinery.
- Pardalos, P. M., Zilinskas, A., and Zilinskas, J. (2018). *Non-Convex Multi-Objective Optimization*. Springer Optimization and Its Applications. Springer Cham.
- Pareto, V. (1964). Cours d'Economie Politique. Libraire Droz, Genève. (the first edition in 1986).
- Parikh, P. K., Savjani, J. K., Gajjar, A. K., and Chhabria, M. T. (2023). *Bioinformatics and Cheminformatics Tools in Early Drug Discovery*, chapter 8, pages 147–181. John Wiley & Sons, Ltd.
- Praditwong, K. and Yao, X. (2006). A new multi-objective evolutionary optimisation algorithm: The two-archive algorithm. In 2006 International Conference on Computational Intelligence and Security, volume 1, pages 286–291.
- Price, K., Storn, R. M., and Lampinen, J. A. (2005). *Differential Evolution: A Practical Approach to Global Optimization (Natural Computing Series)*. Springer-Verlag, Berlin, Heidelberg.
- Purshouse, R. C. and Fleming, P. J. (2007). On the evolutionary optimization of many conflicting objectives. *IEEE Trans. on Evolutionary Computation*, 11(6):770–784.
- Raghavendra, N. M., Pingili, D., Kadasi, S., Mettu, A., and Prasad, S. (2018). Dual or multi-targeting inhibitors: The next generation anticancer agents. *European Journal of Medicinal Chemistry*, 143:1277–1300.
- Rahimi, I., Gandomi, A. H., Chen, F., and Mezura-Montes, E. (2023). A review on constraint handling techniques for population-based algorithms: from single-objective to multi-objective optimization. *Archives of Computational Methods in Engineering*, 30(3):2181–2209.
- Rocha, G. K., Angelo, J. S., Santos, K. B., Custódio, F. L., Dardenne, L. E., and Barbosa, H. J. (2017). Using an aggregation tree to arrange energy function terms for protein structure prediction. In 2017 IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB), pages 1–7.
- Rosenthal, S. and Borschbach, M. (2017). Design perspectives of an evolutionary process for multi-objective molecular optimization. In Trautmann, H., Rudolph, G., Klamroth, K., Schütze, O., Wiecek, M., Jin, Y., and Grimme, C., editors, *Evolutionary Multi-Criterion Optimization*, pages 529–544, Cham. Springer International Publishing.
- Sabe, V. T., Ntombela, T., Jhamba, L. A., Maguire, G. E., Govender, T., Naicker, T., and Kruger, H. G. (2021). Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. *European Journal of Medicinal Chemistry*, 224:113705.
- Safi, H. H., Ucan, O. N., and Bayat, O. (2018). On the real world applications of many-objective evolutionary algorithms. In *Proceedings of the First International Conference on Data Science, E-Learning and Information Systems*, DATA '18, page 6, New York, NY, USA. Association for Computing Machinery.
- Sanchez-Lengeling, B., Outeiral, C., Guimaraes, G., and Aspuru-Guzik, A. (2017). Optimizing distributions over molecular space. an objective-reinforced generative adversarial network for inverse-design chemistry (organic).
- Santos, K. B., Guedes, I. A., Karl, A. L. M., and Dardenne, L. E. (2020). Highly flexible ligand docking: Benchmarking of the dockthor program on the leads-pep protein–peptide data set. *Journal of Chemical Information and Modeling*, 60(2):667–683.
- Sato, H. and Ishibuchi, H. (2023). Evolutionary many-objective optimization: Difficulties, approaches, and discussions. *IEEJ Transactions on Electrical and Electronic Engineering*.
- Saxena, D. K., Duro, J. a. A., Tiwari, A., Deb, K., and Zhang, Q. (2013). Objective reduction in many-objective optimization: Linear and nonlinear algorithms. *IEEE Trans. on Evolutionary Computation*, 17(1):77–99.
- Schoenmaker, L., Béquignon, O. J. M., Jespers, W., and van Westen, G. J. P. (2023). Uncorrupt smiles: a novel approach to de novo design. *Journal of Cheminformatics*, 15(1):22.

- Slowik, A. and Kwasnicka, H. (2020). Evolutionary algorithms and their applications to engineering problems. *Neural Computing and Applications*, 32(16):12363–12379.
- Srinivas, N. and Deb, K. (1994). Muiltiobjective optimization using nondominated sorting in genetic algorithms. *Evolutionary Computation*, 2(3):221–248.
- Trivedi, A., Srinivasan, D., Sanyal, K., and Ghosh, A. (2017). A survey of multiobjective evolutionary algorithms based on decomposition. *IEEE Trans. on Evolutionary Computation*, 21(3):440–462.
- Trott, O. and Olson, A. J. (2010). Autodock vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Journal of Computational Chemistry*, 31(2):455–461.
- Ursem, R. K. and Justesen, P. D. (2012). Multi-objective distinct candidates optimization: Locating a few highly different solutions in a circuit component sizing problem. *Applied Soft Computing*, 12(1):255–265.
- Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., and Kopple, K. D. (2002). Molecular properties that influence the oral bioavailability of drug candidates. *Journal of medicinal chemistry*, 45(12):2615–2623.
- Verel, S., Liefooghe, A., Jourdan, L., and Dhaenens, C. (2013). On the structure of multiobjective combinatorial search space: MNK-landscapes with correlated objectives. *European Journal of Operational Research*, 227(2):331–342.
- Verhellen, J. (2022). Graph-based molecular pareto optimisation. Chem. Sci., 13:7526–7535.
- Vinkers, H. M., de Jonge, M. R., Daeyaert, F. F. D., Heeres, J., Koymans, L. M. H., van Lenthe, J. H., Lewi, P. J., Timmerman, H., Van Aken, K., and Janssen, P. A. J. (2003). Synopsis: Synthesize and optimize system in silico. *Journal of Medicinal Chemistry*, 46(13):2765–2773. PMID: 12801239.
- von Lücken, C., Brizuela, C., and Barán, B. (2019). An overview on evolutionary algorithms for many-objective optimization problems. *WIREs Data Mining and Knowledge Discovery*, 9(1):e1267.
- Wang, H., Jiao, L., and Yao, X. (2015). Two_arch2: An improved two-archive algorithm for many-objective optimization. *IEEE Transactions on Evolutionary Computation*, 19(4):524–541.
- Wang, H., Wang, M., Xu, X., Gao, P., Xu, Z., Zhang, Q., Li, H., Yan, A., Kao, R. Y.-T., and Sun, H. (2021). Multi-target mode of action of silver against staphylococcus aureus endows it with capability to combat antibiotic resistance. *Nature Communications*, 12(1).
- Wang, M., Wang, Z., Sun, H., Wang, J., Shen, C., Weng, G., Chai, X., Li, H., Cao, D., and Hou, T. (2022). Deep learning approaches for de novo drug design: An overview. *Current Opinion in Structural Biology*, 72:135–144.
- Xia, Y., Huang, J., Li, X., Liu, Y., Zheng, J., and Zou, J. (2023). A many-objective evolutionary algorithm based on indicator and decomposition. *Mathematics*, 11(2).
- Xu, Q., Xu, Z., and Ma, T. (2020). A survey of multiobjective evolutionary algorithms based on decomposition: Variants, challenges and future directions. *IEEE Access*, 8:41588–41614.
- Yuan, J., Liu, H.-L., Gu, F., Zhang, Q., and He, Z. (2021). Investigating the properties of indicators and an evolutionary many-objective algorithm using promising regions. *IEEE Transactions on Evolutionary Computation*, 25(1):75–86.
- Yuan, Y., Ong, Y.-S., Gupta, A., and Xu, H. (2018). Objective reduction in many-objective optimization: Evolutionary multiobjective approaches and comprehensive analysis. *IEEE Transactions on Evolutionary Computation*, 22(2):189–210.
- Yuan, Y., Pei, J., and Lai, L. (2011). Ligbuilder 2: A practical de novo drug design approach. *Journal of Chemical Information and Modeling*, 51(5):1083–1091. PMID: 21513346.
- Yuan, Y., Xu, H., Wang, B., and Yao, X. (2016). A new dominance relation-based evolutionary algorithm for many-objective optimization. *IEEE Trans. on Evolutionary Computation*, 20(1):16–37.
- Zhang, Q. and Li, H. (2007). Moea/d: A multiobjective evolutionary algorithm based on decomposition. *IEEE Trans. on Evolutionary Computation*, 11(6):712–731.
- Zhang, Q., Zhou, A., Zhao, S., Suganthan, P., Liu, W., and Tiwari, S. (2008). Multiobjective optimization test instances for the cec 2009 special session and competition. *Mechanical Engineering*.
- Zhang, X., Guo, Y., Yang, J., Li, D., Wang, Y., and Zhao, R. (2022). Many-objective evolutionary algorithm based agricultural mobile robot route planning. *Computers and Electronics in Agriculture*, 200:107274.
- Zhu, S., Xu, L., Goodman, E., Deb, K., and Lu, Z. (2022). A general framework for enhancing relaxed Pareto dominance methods in evolutionary many-objective optimization. *Natural Computing*, pages 1–27.
- Zięba, A., Stępnicki, P., Matosiuk, D., and Kaczor, A. A. (2022). What are the challenges with multi-targeted drug design for complex diseases? *Expert Opinion on Drug Discovery*, 17(7):673–683. PMID: 35549603.

- Zitzler, E. and Künzli, S. (2004). Indicator-based selection in multiobjective search. In Yao, X., Burke, E. K., Lozano, J. A., Smith, J., Merelo-Guervós, J. J., Bullinaria, J. A., Rowe, J. E., Tiňo, P., Kabán, A., and Schwefel, H.-P., editors, *Parallel Problem Solving from Nature PPSN VIII*, pages 832–842. Springer Berlin Heidelberg.
- Zitzler, E., Laumanns, M., and Thiele, L. (2001). Spea2: Improving the strength Pareto evolutionary algorithm. Technical report, ETH Zurich, Computer Engineering and Networks Laboratory.
- Zitzler, E. and Thiele, L. (1998). An evolutionary algorithm for multiobjective optimization: the strength Pareto approach. Technical report, ETH Zurich, Computer Engineering and Networks Laboratory.
- Zitzler, E. and Thiele, L. (1999). Multiobjective evolutionary algorithms: a comparative case study and the strength Pareto approach. *IEEE Trans. on Evolutionary Computation*, 3(4):257–271.
- Zitzler, E., Thiele, L., Laumanns, M., Fonseca, C., and da Fonseca, V. (2003). Performance assessment of multiobjective optimizers: an analysis and review. *IEEE Trans. on Evolutionary Computation*, 7(2):117–132.
- Zou, J., Zhang, Z., Zheng, J., and Yang, S. (2021). A many-objective evolutionary algorithm based on dominance and decomposition with reference point adaptation. *Knowledge-Based Systems*, 231:107392.